IRONDisc Medicine, Inc.

1. Oct 22, 2026On October 20, 2026, Disc Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule I thereto (the …Material agreement entered · Form 8-K
2. Oct 19, 2026Webcast Presentation On October 19, 2026, the Company will host a webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (“EPP”)Regulation FD disclosure · Form 8-K
3. Sep 10, 2026On September 9, 2026, the Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B. In the trial, following …Regulation FD disclosure · Form 8-K
4. Jul 30, 2026Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
5. Jun 30, 2026On June 25, 2026, Disc Medicine, Inc. (the “Company”) entered into a First Amendment to Loan Agreement (the “Amendment”) to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the “Loan Agreement”) among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and …Material agreement entered · Form 8-K
6. May 5, 2026Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
7. Feb 27, 2026On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management began implementing, a restructuring plan (the “Restructuring Plan”) to better align the Company’s workforce with its near-term strategic priorities following the receipt of a complete response letter from the …Exit or disposal costs (restructuring) · Form 8-K
8. Feb 26, 2026Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
9. Feb 17, 2026Bitopertin Regulatory Update February 2026.Regulation FD disclosure · press release
10. Feb 13, 2026On February 13, 2026, the Company received a CRL from the FDA for the Company’s NDA for bitopertin as a treatment for patients with EPP.Regulation FD disclosure · Form 8-K
11. Jan 12, 2026Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.